Make of this what you will.
Tracking the FDA advisory panel meeting on Covid-19 vaccines for kids
(The abstainer)
4:25 p.m.: Michael Kurilla, director of the division of clinical innovation at the National Institutes of Health’s National Center for Advancing Translational Sciences, was the VRBPAC member who abstained.
(The vote)
4:16 p.m.: The panel voted on the following question:
Based on the totality of scientific evidence available, do the benefits of the Pfizer- BioNTech Covid-19 vaccine when administered as a 2-dose series (10 micrograms each dose, 3 weeks apart) outweigh its risks for use in children 5-11 years of age?
Yes: 17 ←
No: 0
Abstain: 1 ← Why?
—
(18) Members total
(1) Abstained
(17) = Unanimous (Yes)
Hmm
https://www.statnews.com/2021/10/26/pfizer-covid19-vaccine-kids-vrbpac-fda/